A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain - 15/11/12
, Ploykaew Tansangngam, MD b , Suthaporn Lumlertgul, MD b , Atthasit Komindr, MD b Abstract |
Introduction |
Acute, severe dyspeptic pain is a common condition in the emergency department. Despite the traditional “GI cocktail” (GI indicates gastrointestinal), an intravenous (IV) proton pump inhibitor (PPI), a novel acid-lowering drug, has recently been used to treat this condition. The aim of this study was to evaluate the immediate effect of IV pantoprazole in addition to the conventional GI cocktail in the relief of severe dyspeptic pain.
Methods |
This double-blind, randomized, controlled study was conducted in the emergency department of an urban tertiary-care hospital from January 2011 to October 2011. Selected patients with severe dyspeptic pain were randomized to treatment with a placebo, antacid, and antispasmodic (conventional group) or IV pantoprazole, antacid, and antispasmodic (pantoprazole group). The self-reported 100-mm visual analog scale score, adverse effects, and overall satisfaction were evaluated in 15-minute intervals for 60 minutes.
Results |
Eighty-seven eligible cases were enrolled in the study. Forty-four and 43 patients were randomized in the conventional group and pantoprazole group, respectively. There was no difference in the mean 60-minute visual analog scale scores between the treatment groups. The rate of “responders,” additional drug use, adverse effects, and patient satisfaction were similar between the groups.
Conclusion |
Intravenous PPI provides no additional benefit over the conventional GI cocktail in the relief of acute, severe dyspeptic pain. Because of its neutral effect and higher cost, the use of IV PPI to treat such conditions should be discouraged in general clinical practice.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | Conflict of interest: M.K. received one third of the total amount of intravenous pantoprazole from Merck Sharp & Dohme. The company did not provide other forms of financial support to the study and was not involved in any part of the study design, patient enrollment, data collection and analysis, or manuscript drafting. The authors declared no conflicts of interest. This study was funded by Rachadapiseksompoch Fund Grant No. RA6/54(1), Faculty of Medicine, Chulalongkorn University. |
Vol 30 - N° 9
P. 1737-1742 - novembre 2012 Retour au numéro
Article précédent
- An electrocardiogram technician improves in-hospital first medical contact-to-electrocardiogram times: a cluster randomized controlled interventional trial
- Raphael van Tulder, Dominik Roth, Christoph Weiser, Benedikt Heidinger, Harald Herkner, Wolfgang Schreiber, Christof Havel
- Does ED crowding decrease the number of procedures a physician in training performs? A prospective observational study
- Clare L. Atzema, R. Alexandra Stefan, Refik Saskin, Greg Michlik, Peter C. Austin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?